Masimo to Report First Quarter 2023 Financial Results After Market Close on Tuesday, May 9Business Wire • 04/25/23
Masimo Opioid Halo™ Granted De Novo for the First and Only FDA-Authorized Opioid Overdose Prevention and Alert SystemBusiness Wire • 04/03/23
Masimo Unveils the Future of Health Tracking and Smart Wearables with the Pre-Sale Launch of the Freedom™ SmartwatchBusiness Wire • 03/28/23
New Study Finds That Masimo PVi® Reliably Predicted Fluid Responsiveness in Young Children Undergoing NeurosurgeryBusiness Wire • 03/09/23
Masimo and Temple Health Form Innovation Collaboration with Focus on Hospital Automation and Telehealth InitiativesBusiness Wire • 03/07/23
New Study Evaluates the Use of Masimo PVi® As an Indicator of Fluid Responsiveness to Guide Goal-Directed Fluid Therapy in Adult Neurosurgical PatientsBusiness Wire • 03/06/23
CalSTRS Joins Politan Capital Management in Legal Action Against Masimo CEO's Employment AgreementBusiness Wire • 03/03/23
Masimo to Present in 44th Annual Raymond James Institutional Investors ConferenceBusiness Wire • 03/02/23